Neupogen went off-patent in the US in 2013 ... Amgen has produced a long-lasting version known Neulasta (pegfilgrastim), which generates sales of just over a billion dollars per quarter.

The lack of competition for Neupogen in the US has propped up the ... white cell stimulator franchise from long-acting follow-up Neulasta (pegfilgrastim), which posted sales of $4.6 billion ...

Neulasta (pegfilgrastim) is a prescription drug used to help prevent infection from certain types of chemotherapy and to treat radiation sickness. Neulasta can interact with certain other ...